Biotherapies in large vessel vasculitis

G. Pazzola, F. Muratore, N. Pipitone, C. Salvarani

Research output: Contribution to journalArticle


The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

Original languageEnglish
Pages (from-to)274-278
Number of pages5
JournalRevue de Medecine Interne
Issue number4
Publication statusPublished - Apr 1 2016


  • Biological therapies
  • Biotherapies
  • Giant cell arteritis
  • Large vessel vasculitis
  • Takayasu arteritis

ASJC Scopus subject areas

  • Gastroenterology
  • Internal Medicine

Fingerprint Dive into the research topics of 'Biotherapies in large vessel vasculitis'. Together they form a unique fingerprint.

  • Cite this

    Pazzola, G., Muratore, F., Pipitone, N., & Salvarani, C. (2016). Biotherapies in large vessel vasculitis. Revue de Medecine Interne, 37(4), 274-278.